Literature DB >> 10727948

Requirements for the mitochondrial import and localization of dihydroorotate dehydrogenase.

J Rawls1, W Knecht, K Diekert, R Lill, M Löffler.   

Abstract

In animals, dihydroorotate dehydrogenase (DHODH) is a mitochondrial protein that carries out the fourth step in de novo pyrimidine biosynthesis. Because this is the only enzyme of this pathway that is localized to mitochondria and because the enzyme is cytosolic in some bacteria and fungi, we carried out studies to understand the mode of targeting of animal DHODH and its submitochondrial localization. Analysis of fractionated rat liver mitochondria revealed that DHODH is an integral membrane protein exposed to the intermembrane space. In vitro-synthesized Drosophila, rat and human DHODH proteins were efficiently imported into the intermembrane space of isolated yeast mitochondria. Import did not alter the size of the in vitro synthesized protein, nor was there a detectable size difference when compared to the DHODH protein found in vivo. Thus, there is no apparent proteolytic processing of the protein during import either in vitro or in vivo. Import of rat DHODH into isolated yeast mitochondria required inner membrane potential and was at least partially dependent upon matrix ATP, indicating that its localization uses the well described import machinery of the mitochondrial inner membrane. The DHODH proteins of animals differ from the cytosolic proteins found in some bacteria and fungi by the presence of an N-terminal segment that resembles mitochondrial-targeting presequences. Deletion of the cationic portion of this N-terminal sequence from the rat DHODH protein blocked its import into isolated yeast mitochondria, whereas deletion of the adjacent hydrophobic segment resulted in import of the protein into the matrix. Thus, the N-terminus of the DHODH protein contains a bipartite signal that governs import and correct insertion into the mitochondrial inner membrane.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10727948     DOI: 10.1046/j.1432-1327.2000.01213.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  29 in total

Review 1.  Mitochondrial Metabolism as a Target for Cancer Therapy.

Authors:  Karthik Vasan; Marie Werner; Navdeep S Chandel
Journal:  Cell Metab       Date:  2020-07-14       Impact factor: 27.287

2.  Pathomechanisms in coenzyme q10-deficient human fibroblasts.

Authors:  Luis C López; Marta Luna-Sánchez; Laura García-Corzo; Catarina M Quinzii; Michio Hirano
Journal:  Mol Syndromol       Date:  2014-07

Review 3.  Interplay of mitochondrial metabolism and microRNAs.

Authors:  Julian Geiger; Louise T Dalgaard
Journal:  Cell Mol Life Sci       Date:  2016-08-25       Impact factor: 9.261

4.  Pyrimidine Pathway-Dependent and -Independent Functions of the Toxoplasma gondii Mitochondrial Dihydroorotate Dehydrogenase.

Authors:  Miryam Andrea Hortua Triana; Daniela Cajiao Herrera; Barbara H Zimmermann; Barbara A Fox; David J Bzik
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

5.  F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase.

Authors:  Jason D Oliver; Graham E M Sibley; Nicola Beckmann; Katharine S Dobb; Martin J Slater; Laura McEntee; Saskia du Pré; Joanne Livermore; Michael J Bromley; Nathan P Wiederhold; William W Hope; Anthony J Kennedy; Derek Law; Mike Birch
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-25       Impact factor: 11.205

6.  Atovaquone tolerance in Plasmodium falciparum parasites selected for high-level resistance to a dihydroorotate dehydrogenase inhibitor.

Authors:  Jennifer L Guler; John White; Margaret A Phillips; Pradipsinh K Rathod
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

Review 7.  Mitochondrial miRNAs in diabetes: just the tip of the iceberg.

Authors:  Rohini Baradan; John M Hollander; Samarjit Das
Journal:  Can J Physiol Pharmacol       Date:  2017-05-03       Impact factor: 2.273

8.  Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.

Authors:  Liangxian Cao; Marla Weetall; Christopher Trotta; Katherine Cintron; Jiyuan Ma; Min Jung Kim; Bansri Furia; Charles Romfo; Jason D Graci; Wencheng Li; Joshua Du; Josephine Sheedy; Jean Hedrick; Nicole Risher; Shirley Yeh; Hongyan Qi; Tamil Arasu; Seongwoo Hwang; William Lennox; Ronald Kong; Janet Petruska; Young-Choon Moon; John Babiak; Thomas W Davis; Allan Jacobson; Neil G Almstead; Art Branstrom; Joseph M Colacino; Stuart W Peltz
Journal:  Mol Cancer Ther       Date:  2018-10-23       Impact factor: 6.261

Review 9.  Energetic depression caused by mitochondrial dysfunction.

Authors:  Frank Norbert Gellerich; Sonata Trumbeckaite; Tobias Müller; Marcus Deschauer; Ying Chen; Zemfira Gizatullina; Stephan Zierz
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

10.  The effect of mitochondrial dysfunction on cytosolic nucleotide metabolism.

Authors:  Claus Desler; Anne Lykke; Lene Juel Rasmussen
Journal:  J Nucleic Acids       Date:  2010-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.